Investigators assessed the relationship between intraoperative measurements obtained via laser speckle contrast imaging and outcomes following total thyroidectomy.
Graves disease and other thyroid-related diseases of the eyes may benefit from teprotumumab therapy, according to a multicenter, multinational study.
The objective of the study was to estimate the shared genetic influence on overt Hashimoto thyroiditis and Graves disease and to examine if the heritability for them differs between men and women.
Several factors may predict normal thyroid function after radioiodine therapy for hyperthyroidism, including older age and larger volume of thyroid gland.
Researchers identified predictors of biochemical treatment response to antithyroid drugs, specifically methimazole, in patients with Graves disease.
The American Association of Endocrine Surgeons has published the first comprehensive guidelines for safe, effective, and appropriate thyroidectomy.
In most cases of overt hyperthyroidism, patients present with a constellation of symptoms, and appropriate treatment depends on the underlying mechanism.
Patients with Graves disease in association with other autoimmune diseases had a 4-fold higher rate of transition from initial hypothyroidism to hyperthyroidism compared with patients who had isolated Graves disease.
Teprotumumab is an investigational fully human monoclonal antibody that works by inhibiting the insulin-like growth factor 1 receptor.
Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease.
